The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis

Cancer-associated thrombosis (CAT) carries significant morbidity and mortality. Low-molecular-weight heparin (LMWH) remains the standard of care, with recent systematic studies suggesting the efficacy and safety of rivaroxaban in the treatment of CAT. Uncertainty, however, remains regarding rivaroxa...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Appl Thromb Hemost
Main Authors: Mohamed, Mouhand F. H., ElShafei, Mohamad Nabil, Ahmed, Mohamed Badie, Abdalla, Lina O., Ahmed, Israa, Elzouki, Abdel-Naser, Danjuma, Mohammed ibn-mas’ud
Formato: Artigo
Idioma:Inglês
Publicado: SAGE Publications 2021
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930650/
https://ncbi.nlm.nih.gov/pubmed/33651658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1076029620940046
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares